COPENHAGEN, June 22 (Reuters) - Danish biotech firm Genmab (GEN.CO: Quote, Profile, Research) said on Thursday its drug AMG 714, which targets rheumatoid arthritis, had successfully achieved a reduction in the effects of the disease in a majority of 55 patients in a Phase II study.
